Recommendations for tuberculosis screening before initiation of TNF - Inhibitor treatment in rheumatic diseases;Empfehlungen für das Tuberkulosescreening vor Gabe von TNF - Inhibitoren bei rheumatischen Erkrankungen

Pneumologie

Volumn 63, Issue 6, 2009, Pages 329-334

  Diel, R ^a,c   Hauer, B ^a   Loddenkemper, R ^a   Manger, B ^b,d   Kruger K ^b,e  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^b Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e Rheumatologisches Praxiszentrum St Bonifatius   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BCG VACCINE; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; METHOTREXATE; PHYTOHEMAGGLUTININ; PREDNISOLONE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANAMNESIS; AUTOIMMUNE DISEASE; CHEMOPROPHYLAXIS; COOMBS TEST; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GRANULOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TUBERCULOSIS; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCREENING; SENSITIVITY AND SPECIFICITY; SKIN INDURATION; T LYMPHOCYTE; THORAX RADIOGRAPHY; TUBERCULIN TEST; DRUG ANTAGONISM; GERMANY; MASS SCREENING; PRACTICE GUIDELINE; RHEUMATOLOGY; STANDARD; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; GERMANY; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; RHEUMATOLOGY; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69249220409     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1214673     Document Type: Review

References (46)

1. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005; 74: 35-39
2. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265
3. Wolfe F, Michaud K, Anderson J et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379 (Pubitemid 38198820)
4. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
5. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44: 714-720
6. Schiff MH, Burmester GR, Kent JM et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894
7. Keane J, Breshinan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 20: 443-449
8. Paul-Ehrlich-Institut und Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (Februar 2002). Empfehlungen zur Diagnose und Prävention der latenten Tuberkulose bei Patienten vor Beginn der Behandlung mit Remicade (Infliximab), zitiert in: Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J und die Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie. Neufassung der Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlichen Erkrankungen (Stand März 2006). www.dgrh.de/fileadmin/ media/ Qualitaetssicherung/Therapie-Empfehlungen/TNF-Blocker-06.pdf; Stand: 12.12.2008
9. Furst DE, Cush J, Kaufmann S et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2006; 61: ii62-ii63
10. Tissot F, Zanetti G, Francioli P et al. Influence of Bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Inf Dis 2005; 40: 211-217
11. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose. Pneumologie 2007; 58: 657-665
12. Simon K, Gutland M. Die Tuberkulinprobe in der Klinik -Dosierung und Wertung. Prax Klin Pneumol 1988; 42: 423-426
13. Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Clin Rheumatol 2002; 16: 707-722
14. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferongamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007; 131: 1424-1434 (Pubitemid 46762348)
15. Diel R, Ernst M, Döscher G et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. Eur Respir J 2006; 28: 16-23
16. Diel R, Nienhaus A, Lange C et al. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respiratory Research 2006; 7: 77
17. Matulis G, Jüni P, Villiger PM et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases -perform-ance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008; 67: 84-90
18. Diel R, Nienhaus A, Lange C et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: 35-44 (Pubitemid 44914258)
19. Piana F, Codecasa LR, Cavallerio P et al. Use of a T-cell based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34
20. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. NEJM 2004; 350: 2060-2067
21. Diel R, Loddenkemper R, Meywald-Walter K et al. Predictive value of a whole-blood IFN-y assay for the development of active TB disease after recent infection with M. tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170
22. Panayi G, Corrigall V, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: 1-18
23. MowWS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313
24. Malipeddi AS, Rajendran R, Kallarackal G. Disseminated tuberculosis after anti-TNFα treatment. Lancet 2007; 369: 162
25. Efthimiou P, Sood S. Quantiferon TB gold test: The new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis 2007; 66: 276
26. Raval A, Akhavan-Toyserkani G, Brinker A et al. Brief communication: characteristics of spontaneous cases of tuberculosis associated with Infliximab. Ann Intern Med 2007; 147: 699-702
27. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1361
28. Vassilopoulos D, Stamoulis N, Hadziyannis E et al. Usefulness of Enzyme-Linked Immunospot Assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008; 35: 1464 [Epub ahead of print March 2008] (Pubitemid 352000805)
29. Sellam J, Hamdi H, Roy C et al. RATIO (Research Axed on Tolerance of Biotherapies) Study Group. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-1615
30. Bartalesi F, Vicidomini S, Goletti D et al. QuantiFERON-TB Gold and TST are both useful for latent TB screening in autoimmune diseases. Eur Respir J 2009; 33: 586-593 [Epub 2008 Dec 1]
31. Greenberg JD, Reddy SM, Schloss SG et al. Comparison of an in vitro Tuberculosis Interferon-gamma Assay with Delayed-type Hypersensitivity Testing for Detection of Latent Mycobacterium tuberculosis: A Pilot Study in Rheumatoid Arthritis. J Rheumatol 2008; 35: 770-775
32. Gómez-Rheino JJ, Carmona L, Descalzo MÁ. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis & Rheumatism 2007; 57: 756-761
33. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155
34. Beglinger C, Dudler J, Mottet C et al. Screening for tuberculosis infection before initiation of anti-TNF-α therapy. Swiss Med Wkly 2007; 137: 621-622
35. Arend S, Leyten EM, Franken WP et al. A patient with de novo tuberculosis during anti-tumor necrosis factor therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45: 1470-1475
36. Jeong YJ, Lee KS. Pulmonary tuberculosis: Up-to-date imaging and management. Am J Roentgenol 2008; 191: 834-844
37. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 27: 19-30
38. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al. BIOBADASER Group . Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772
39. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose. Latente tuberkulöse Infektion: Empfehlungen zur präventiven Therapie bei Erwachsenen in Deutschland. Pneumologie 2004; 58: 255-270
40. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Crit Care Med 2004; 170: 832-835
41. Sichletidis L, Settas L, Spyratos D et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132
42. Ledingham J, Deighton C on behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Guidelines. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44: 157-163
43. Dixon WG, Hyrich KL, Watson KD, Lunt M BSRBR Control Centre Consortium, Symmons DPM, on behalf of the BSR Biologics Register and Epidemiology Unit, University of Manchester, Manchester, United Kingdom. EULAR 2008 [THU0134]. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results form the BSR Biologics Register (BSRBR). Ann Rheum Dis 2008; 67 (Suppl II): 178
44. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha -California, 2002-2003. MMWR 2004; 53: 683-686
45. Dosanjh DP, Hinks TS, Innes JA et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008; 148: 325-336
46. Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS ONE 2008; 3: e3901 [Epub 2008 Dec 9]